ERBB2 and breast cancer: A similar synergistic cell growth inhibitory effect (~50%) was also observed for Lapatinib in combination with 25 μM Deferiprone in the other tested HER2+ BC cells, SKBR3 and BT474 (p < 0.001), as shown in Supplementary Figure 3.